Features of age-related macular degeneration in a black population. The Barbados Eye Study Group, Arch Ophthalmol Chic Ill, vol.113, pp.728-763, 19601995. ,
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, vol.2, issue.13, pp.70145-70146, 2014. ,
Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE), Arch Ophthalmol Chic Ill, vol.124, pp.529-564, 1960. ,
,
, Cigarette smoking and age-related macular degeneration in the EUREYE Study, Ophthalmology, vol.114, pp.1157-63, 2007.
The epidemiology of age-related macular degeneration, Am J Ophthalmol, vol.137, pp.486-95, 2004. ,
Features of age-related macular degeneration in a black population. The Barbados Eye Study Group, Arch Ophthalmol Chic Ill, vol.113, pp.728-763, 19601995. ,
The prevalence of age-related maculopathy by geographic region and ethnicity, Prog Retin Eye Res, vol.18, pp.371-89, 1999. ,
Risk factors for age-related macular degeneration: Pooled findings from three continents, Ophthalmology, vol.108, pp.697-704, 2001. ,
Fiveyear incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study, Ophthalmology, vol.121, pp.1766-72, 2014. ,
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch Ophthalmol Chic Ill, vol.120, pp.338-384, 1960. ,
The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study, Ophthalmology, vol.104, pp.7-21, 1997. ,
, Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration, Arch Ophthalmol Chic Ill, vol.111, pp.1200-1209, 19601993.
, Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment, PloS One, vol.9, p.101072, 2014. ,
Targeting VEGF-A to treat cancer and agerelated macular degeneration, Annu Rev Med, vol.58, pp.491-504, 2007. ,
Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, vol.145, pp.239-287, 2008. ,
double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2, Am J Ophthalmol, vol.150, pp.315-324, 2010. ,
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study, Ophthalmology, vol.116, pp.57-65, 2009. ,
,
, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, vol.355, pp.1432-1476, 2006.
,
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study, Ophthalmology, vol.118, pp.831-840, 2011. ,
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix-week results of the VIEW studies, Ophthalmology, vol.121, pp.193-201, 2014. ,
HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration, Ophthalmology, vol.119, pp.1175-83, 2012. ,
Twentyfour-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration, Ophthalmology, vol.121, pp.2181-92, 2014. ,
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact, Ophthalmology, vol.117, pp.2134-2174, 2010. ,
Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years, Retina Phila Pa, vol.34, pp.1531-1539, 2014. ,
, RETINAL DISEASES: A Literature Review and Consensus Recommendations, vol.35, pp.1489-506, 2015.
Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen, Am J Ophthalmol, vol.159, pp.3-8, 2015. ,
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results, Eye Lond Engl, vol.29, pp.450-451, 2015. ,
Two-year outcome of an observeand-plan regimen for neovascular age-related macular degeneration treated with Aflibercept ,
, Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol, vol.255, pp.2127-2161, 2017.
Ranibizumab according to need: a treatment for age-related macular degeneration, Am J Ophthalmol, vol.143, pp.679-80, 2007. ,
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study, Ophthalmology, vol.125, pp.57-65, 2018. ,
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results, Ophthalmology, vol.122, pp.2514-2536, 2015. ,
Two year outcomes of « TREAT AND EXTEND » intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration, Retina Phila Pa, vol.38, pp.20-28, 2018. ,
Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration, Br J Ophthalmol, vol.100, pp.1341-1346, 2016. ,
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact, Ophthalmology, vol.117, pp.2134-2174, 2010. ,
A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration, Retina Phila Pa, vol.33, pp.1351-1359, 2013. ,
,
, Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study, Ophthalmology, vol.118, pp.663-71, 2011.
The Treat-andExtend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis, Am J Ophthalmol, vol.192, pp.184-97, 2018. ,
Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration ,
, Am J Ophthalmol, vol.158, pp.532-538, 2014.
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times, Br J Ophthalmol, vol.100, pp.1494-1502, 2016. ,
,
Retina Phila Pa, 2017. ,
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update, Clin Ophthalmol Auckl NZ, vol.11, pp.1957-66, 2017. ,
, Résumé Évaluation en condition de vraie vie du treat and extend chez les patients atteints de dégénérescence maculaire liée à l